Claims for Patent: 4,029,782

Summary for Patent: 4,029,782

Title:	Cefazolin suspension for parenteral administration
Abstract:	A pharmaceutical suspension for parenteral administration is provided which comprises finely divided crystals of cefazolin suspended in a vehicle composed of water, a pharmaceutically acceptable surfactant, lecithin and a viscosity adjusting agent or agents. Methods are also provided for preparing such a suspension.
Inventor(s):	Bornstein; Michael (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	05/573,283
Patent Claims:	1. A pharmaceutical suspension for parenteral administration comprising from about 10 to about 65 percent (W/V) of cefazolin, from about 0.1 to about 1.0 percent of lecithin, from about 0.1 to about 1.0 percent (W/V) of a pharmaceutically acceptable surfactant, from about 0.1 to about 2.0 percent (W/V) of a viscosity adjusting agent selected from the group consisting of povidone and sodium carboxymethylcellulose or a combination thereof, and water for injection q.s. to 100 percent by volume. 2. The suspension of claim 1 wherein said pharmaceutically acceptable surfactant is polysorbate 80. 3. The suspension of claim 1 wherein said viscosity adjusting agent is povidone. 4. The suspension of claim 1 wherein said viscosity adjusting agent is sodium carboxymethylcellulose. 5. The suspension of claim 1 wherein a combination of povidone and sodium carboxymethylcellulose is utilized as the viscosity adjusting agent. 6. The suspension of claim 1 comprised of: a) about 50 percent (W/V) of the cefazolin, b) about 0.5 percent (W/V) of the lecithin, c) about 0.3 percent (W/V) of the pharmaceutically acceptable surfactant, d) about 0.5 percent (W/V) of the viscosity adjusting agent, and, e) water for injection q.s. to 100 percent by volume. 7. The suspension of claim 6 wherein the pharmaceutically acceptable surfactant is polysorbate 80. 8. The suspension of claim 6 wherein the viscosity adjusting agent is povidone. 9. The suspension of claim 6 wherein the viscosity adjusting agent is sodium carboxymethylcellulose. 10. The suspension of claim 6 wherein a combination of povidone and sodium carboxymethylcellulose is utilized as the viscosity adjusting agents. 11. A method of preparing a storage stable pharmaceutical suspension of cefazolin for parenteral administration comprising: a. combining, with agitation, from about 0.1 to about 1.0 parts by weight of a pharmaceutically acceptable surfactant with about 35 parts by volume of water for injection, U.S.P., said water having been previously heated to about 80.degree. C.; b. adding to the preparation from a), with agitation, from about 0.1 to about 1.0 parts by weight of lecithin; c. adding to the preparation from b), with agitation, from about 0.1 to about 2.0 parts by weight of a viscosity adjusting agent selected from the group consisting of povidone and sodium carboxymethylcellulose or combination thereof; d. sterilizing the preparation from c) by autoclaving for about 60 minutes at 115.degree. to 125.degree. C. and 20 psig; e. cooling the preparation from d) to room temperature; f. adding to the preparation from e), with agitation, from about 10 to about 65 parts by weight of cefazolin previously reduced to a particle size wherein at least 80 percent are <10 .mu.m and all are <100 .mu.m; and g. adding to the preparation from f), with agitation, sufficient sterile water for injection, U.S.P. to q.s. said suspension to 100 party by volume. 12. The method of claim 11 wherein the pharmaceutically acceptable surfactant utilized in step a) is polysorbate 80. 13. The method of claim 11 wherein the viscosity adjusting agent utilized in step c) is povidone. 14. The method of claim 11 wherein the viscosity adjusting agent utilized in step c) is sodium carboxymethylcellulose. 15. The method of claim 11 wherein a combination of povidone and sodium carboxymethylcellulose is utilized in step c) as the viscosity adjusting agent. 16. The method of claim 11 comprising: a. combining, with agitation, about 0.3 parts by weight of the pharmaceutically acceptable surfactant with about 35 parts by volume of water for injection, U.S.P., said water having been previously heated to about 80.degree. C.; b. adding to the preparation from a), with agitation, about 0.5 parts by weight of lecithin; c. adding to the preparation from b), with agitation, about 0.5 parts by weight of the viscosity adjusting agent; d. sterilizing the preparation from c) by autoclaving for about 60 minutes at 115.degree. to 125.degree. C. and 20 psig; e. cooling the preparation from d) to room temperature; f. adding to the preparation from e), with agitation, about 50 parts by weight of cefazolin previously reduced to a particle size wherein at least 80 percent are <10 .mu.m and all are <100 .mu.m; and g. adding to the preparation from f), with agitation, sufficient sterile water for injection, U.S.P. to q.s., said suspension to 100 parts by volume. 17. The method of claim 15 wherein the pharmaceutically acceptable surfactant utilized in step a) is polysorbate 80. 18. The method of claim 15 wherein the viscosity adjusting agent utilized in step c) is povidone. 19. The method of claim 15 wherein the viscosity adjusting agent utilized in step c) is sodium carboxymethylcellulose. 20. The method of claim 15 wherein the combination of povidone and sodium carboxymethylcellulose is utilized in step c) as the viscosity adjusting agent.

Details for Patent 4,029,782

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23